Logo image of SCTL

SOCIETAL CDMO INC (SCTL) Stock Fundamental Analysis

NASDAQ:SCTL - US75629F1093 - Common Stock

1.1 USD
+0.01 (+0.92%)
Last: 4/5/2024, 8:19:35 PM
1.09 USD
-0.01 (-0.91%)
After Hours: 4/5/2024, 8:19:35 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SCTL. SCTL was compared to 193 industry peers in the Pharmaceuticals industry. SCTL has a bad profitability rating. Also its financial health evaluation is rather negative. SCTL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SCTL has reported negative net income.
SCTL had a negative operating cash flow in the past year.
SCTL had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SCTL reported negative operating cash flow in multiple years.
SCTL Yearly Net Income VS EBIT VS OCF VS FCFSCTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

SCTL's Return On Assets of -8.64% is fine compared to the rest of the industry. SCTL outperforms 74.37% of its industry peers.
SCTL has a Return On Equity of -22.61%. This is in the better half of the industry: SCTL outperforms 72.86% of its industry peers.
Industry RankSector Rank
ROA -8.64%
ROE -22.61%
ROIC N/A
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCTL Yearly ROA, ROE, ROICSCTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

SCTL's Gross Margin of 19.17% is in line compared to the rest of the industry. SCTL outperforms 49.75% of its industry peers.
In the last couple of years the Gross Margin of SCTL has declined.
The Profit Margin and Operating Margin are not available for SCTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
SCTL Yearly Profit, Operating, Gross MarginsSCTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

SCTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCTL has been increased compared to 1 year ago.
Compared to 5 years ago, SCTL has more shares outstanding
SCTL has a better debt/assets ratio than last year.
SCTL Yearly Shares OutstandingSCTL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
SCTL Yearly Total Debt VS Total AssetsSCTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.24, we must say that SCTL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SCTL (-1.24) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.01 indicates that SCTL is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, SCTL perfoms like the industry average, outperforming 55.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.24
ROIC/WACCN/A
WACC11.28%
SCTL Yearly LT Debt VS Equity VS FCFSCTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

SCTL has a Current Ratio of 1.07. This is a normal value and indicates that SCTL is financially healthy and should not expect problems in meeting its short term obligations.
SCTL has a worse Current ratio (1.07) than 85.93% of its industry peers.
SCTL has a Quick Ratio of 1.07. This is a bad value and indicates that SCTL is not financially healthy enough and could expect problems in meeting its short term obligations.
SCTL has a Quick ratio of 0.86. This is amonst the worse of the industry: SCTL underperforms 83.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.86
SCTL Yearly Current Assets VS Current LiabilitesSCTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.74% over the past year.
Looking at the last year, SCTL shows a small growth in Revenue. The Revenue has grown by 4.91% in the last year.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%

3.2 Future

Based on estimates for the next years, SCTL will show a very strong growth in Earnings Per Share. The EPS will grow by 31.13% on average per year.
Based on estimates for the next years, SCTL will show a quite strong growth in Revenue. The Revenue will grow by 9.11% on average per year.
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SCTL Yearly Revenue VS EstimatesSCTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
SCTL Yearly EPS VS EstimatesSCTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SCTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCTL Price Earnings VS Forward Price EarningsSCTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SCTL indicates a somewhat cheap valuation: SCTL is cheaper than 78.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.26
SCTL Per share dataSCTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

SCTL's earnings are expected to grow with 31.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y31.13%

More info and screens

0

5. Dividend

5.1 Amount

SCTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOCIETAL CDMO INC

NASDAQ:SCTL (4/5/2024, 8:19:35 PM)

After market: 1.09 -0.01 (-0.91%)

1.1

+0.01 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-22 2024-03-22/amc
Earnings (Next)05-08 2024-05-08/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner Change0%
Market Cap116.26M
Analysts78
Price Target1.12 (1.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.57%
Min EPS beat(2)-145.1%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-44.61%
Min EPS beat(4)-145.1%
Max EPS beat(4)1.96%
EPS beat(8)5
Avg EPS beat(8)-15.62%
EPS beat(12)9
Avg EPS beat(12)5.08%
EPS beat(16)10
Avg EPS beat(16)-57.49%
Revenue beat(2)1
Avg Revenue beat(2)0.76%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)6.12%
Revenue beat(4)2
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-4.6%
Max Revenue beat(4)6.12%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)7
Avg Revenue beat(12)1.72%
Revenue beat(16)9
Avg Revenue beat(16)-0.52%
PT rev (1m)-47.2%
PT rev (3m)-47.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.98
P/tB 7.58
EV/EBITDA 27.26
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.9
BVpS0.56
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.64%
ROE -22.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.17%
FCFM N/A
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.06
Cap/Depr 92.47%
Cap/Sales 8.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 0.86
Altman-Z -1.24
F-Score4
WACC11.28%
ROIC/WACCN/A
Cap/Depr(3y)87.57%
Cap/Depr(5y)90.2%
Cap/Sales(3y)8.33%
Cap/Sales(5y)8.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%
EBIT growth 1Y-1334.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year472.86%
EBIT Next 3Y112.66%
EBIT Next 5YN/A
FCF growth 1Y22.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.39%
OCF growth 3YN/A
OCF growth 5YN/A